Levothyroxine Supplementation for Heart Transplant Recipients: A Randomized Control Trial
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This will be a prospective, randomized study performed at a single tertiary referral academic medical center (University of California San Francisco, CA), evaluating the survival benefits of levothyroxine compared with no levothyroxine for patients who have undergone heart transplant. It will be double-blinded and placebo-control; participants will be randomized to receive levothyroxine or receive no levothyroxine.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Participants must be listed for heart transplantation
• Age ≥18 years
• Ability to understand and the willingness to sign a written informed consent document.
Locations
United States
California
University of California, San Francisco
RECRUITING
San Francisco
Contact Information
Primary
Sarah Sullivan
Sarah.sullivan2@ucsf.edu
415-353-7083
Time Frame
Start Date: 2024-03-29
Estimated Completion Date: 2027-03-01
Participants
Target number of participants: 97
Treatments
Experimental: Levothyroxine
Patients will be double-blinded and randomized to receive levothyroxine.
Placebo_comparator: No Levothyroxine
Patients will be double-blinded and randomized to receive no levothyroxine. The placebo will be normal saline.
Related Therapeutic Areas
Sponsors
Leads: University of California, San Francisco